8+ can't-miss Houston business and innovation events for November

where to be

Join us at the Houston Innovation Awards Nov. 13. Courtesy photo

Editor's note: Houston’s innovation calendar is packed this November, with opportunities to connect across climatetech, health care and entrepreneurship. From Greentown Labs’ flagship summit and veteran-led showcases to discussions on medical innovation and startup growth, here's what not to miss and how to register. Please note: this article may be updated to include additional event listings.

Nov. 4 – Greentown Climatetech Summit

Greentown Labs' Climatetech Summit Houston will bring together philanthropists, executives and innovators in the energy transition space. Expect to hear from John Arnold, co-founder and co-chair of Arnold Ventures, and Greentown CEO Georgina Campbell Flatter, who will participate in the day-long event’s keynote fireside chat, along with remarks from Houston Mayor John Whitmire, a course led by TEX-E Executive Director Sandy Guitar and more. Ten Greentown Labs startups will present pitches, and attendees will also be able to meet founders and Greentown members during the afternoon startup showcase.

This event is Tuesday, Nov. 4, from 8 a.m.-4:30 p.m. at Greentown Labs. A networking reception follows from 5-7:30 p.m. at Axelrad Houston. Learn more here.

Nov. 11 – Veterans & Visionaries

Houston Veteran Network will celebrate the entrepreneurial spirit of veterans at its Veterans & Visionaries event. Veteran business owners will have the opportunity to showcase their businesses, connect with investors and participate in speed networking.

This event is Tuesday, Nov. 11, from 2-7 p.m. at the Ion. Find more information here.

Nov. 12 – Energy Drone and Robotics Forum

The Energy Drone + Robotics Coalition will offer a chance for industry leaders, operators and engineers to connect. Attendees will explore real-world uses, hear lessons from successful deployments, and gain practical insights and tools for scaling through various workshops, keynote addresses, Q&As and more.

This event is Wednesday, Nov. 12, from 8 a.m.-5:30 p.m. at the Ion. A Bots & Brews / Industrial AI Connect Reception will be held at Second Daught from 5:30-7:30 p.m. Find more information here.

Nov. 12 – TMC Envision 2025: Showcasing Healthcare Innovation

Celebrate 10 years of TMC Innovation at Envision, which shines a light on how TMC’s health tech companies are shaping the future. The event will feature talks from TMC’s Devin Dunn, Jason Sakamoto and Tom Luby that will focus on hospital innovation, health care policies, Texas-specific funding and regulatory dynamics and more.

This event is Wednesday, Nov. 12, from 3:30-6:30 p.m. at TMC Innovation Factory. Find more information here.

Nov. 13 — 2025 Houston Innovation Awards

Join InnovationMap at Greentown Labs on Nov. 13 for the fifth annual Houston Innovation Awards. Our annual celebration of all things Houston innovation offers an exclusive opportunity to network with leaders in the innovation ecosystem and culminates in the awards ceremony, where this year's winners across 10 prestigious categories will be unveiled. Individual tickets and corporate 10-packs with reserved seating are still available.

This event is Thursday, Nov. 13 at 7 p.m. at Greentown Labs. Get your tickets here.

Nov. 13 – Houston Methodist Leadership Speaker series

Head to the Houston Methodist Tech Hub at Ion to hear the latest installment of the Houston Methodist Leadership Speaker Series. The month’s event will feature Dr. Shlomit Schaal, executive vice president and chief physician executive at Houston Methodist. She is also the president and CEO of the Houston Methodist Physician Organization. Schaal will focus on physician group innovation.

This event is Thursday, Nov. 13, from 4:45-6 p.m. at the Ion. Find more information here.

Nov. 18 – Rice Customer-based Strategy Symposium

Rice University’s Jones Graduate School of Business will present this recurring forum for exchanging innovative ideas on customer-centered strategy planning and execution. The symposium features peer-reviewed research from leading academics with industry trends and insights from executives. Hear from Jones School Dean Peter Rodriguez, Harris County Sheriff Ed Gonzalez, Laura Lopez, SVP of marketing, communications and public relations at Houston Methodist; Farid Virani, CEO of Prime Communications; and several Rice MBA graduates and executives.

This event is Tuesday, Nov. 18, 2025, from 7:30 a.m.-3:00 p.m. at the Ion. Learn more here.

Nov. 20 – Houston Startup Speedrun

Wade Pinder, founder of Product Houston, will host the Houston Startup Speedrun. This intensive and fast-paced program is designed to provide early-stage founders and aspiring entrepreneurs with a comprehensive understanding of the “Startup Founder's Journey” and the Houston startup ecosystem. The event is broken up into 10 consecutive 50-minute sessions, including topics such as “Creating a Compelling Business Plan,” “Operations and Scaling” and others.

This event is Thursday, Nov. 20, from 9 a.m.-7 p.m. at the Ion. Find more information here.

Nov. 20 – State of the Texas Medical Center

The Greater Houston Partnership will present the State of the Texas Medical Center. Hear from William F. McKeon, president and CEO of TMC, and GHP president and CEO Steve Kean as they discuss “the tremendous progress happening in health care delivery and life sciences in the world’s largest medical center.”

This event is Thursday, Nov. 20, from 4-6:30 p.m. at Helix Park. Find more information here.

From Your Site Articles
The partnership between Japan-based Mitsui Fudosan Co. Ltd. and the National Cancer Center will focus on advancing cancer treatments, providing a pathway for Japanese innovators to expand in the U.S. market. Photo courtesy of TMC

TMC launches cancer-focused partnership with Japan

global collaboration

Houston's Texas Medical Center announced the launch of its new TMC Japan BioBridge and Japan-Accelerator Cancer Therapeutics and Medical Devices, or JACT, this month.

The strategic partnership between Japan-based Mitsui Fudosan Co. Ltd. and the National Cancer Center will focus on advancing cancer treatments and providing a pathway for Japanese innovators to expand in the U.S. market. A delegation from TMC recently visited Tokyo, and William F. McKeon, president and CEO of TMC, signed the TMC Japan BioBridge Memorandum of Understanding with Takeshi Ozane, general manager of Mitsui Fudosan, and Hitoshi Nakagama, president of the National Cancer Center of Japan.

“The launch of TMC Japan BioBridge is a vital step forward in connecting two global leaders in healthcare innovation,” McKeon says in a statement. “Japan’s leadership has demonstrated an impressive commitment to advance medical cures and life sciences technologies and through this partnership, we are opening necessary doors for Japanese researchers and innovators to access the US market and collaborate with our TMC ecosystem. Together, we aim to accelerate critical breakthroughs to make a difference for patients all around the world.”

The new JACT will offer cancer-treatment companies a structured process to prepare for a U.S. expansion and will allow for meetings with pharmaceutical companies, hospital systems and investors and provide insights on U.S. regulatory approvals. It'll focus on three key areas, according to the statement:

  1. Milestone development and financial planning
  2. Clinical and regulatory expertise
  3. Strategic partnerships and market insights

“This TMC Japan BioBridge and JACT Program will enable us to promote the advancement of start-up companies aiming to commercialize innovative medical technologies originating in Japan into the U.S." Nakagama says in a statement. "We also hope this collaboration will not be limited to our (Japan Agency for Medical Research and Development)-supported project, but will lead to further cooperation between TMC, NCC, and other Japanese institutions in various fields.”

This is the sixth international strategic partnership for the TMC. It launched its first BioBridge, which focus on partnerships to support international healthcare companies preparing for U.S. expansion, with the Health Informatics Society of Australia in 2016. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.

The Texas Medical Center visited the Netherlands to secure a deal that creates a BioBridge to the country and Houston. Photo courtesy of TMC

TMC again expands global impact with new Netherlands partnership

breaking news

The Texas Medical Center may be based in Houston, but the organization has again grown its global impact.

Since 2016, TMC’s BioBridges have worked with 88 startup companies. Those include strategic alliances with four other countries. Australia, the United Kingdom, Denmark and Ireland are all among TMC’s BioBridges partners. As of today, add the Netherlands to that list.

On September 27, TMC president and CEO, William F. McKeon, and Carmen van Vilsteren, chair of Health~Holland, Top Sector Life Sciences & Health (LSH), signed an agreement in Rotterdam. The TMC Netherlands BioBridge Memorandum of Understanding codifies the innovative goals of the partnership. Essentially, the BioBridge program provides a means for entrepreneurs, researchers, clinicians and industry partners from other countries to access the US market, as well as TMC experts.

“The TMC Netherlands BioBridge represents an unparalleled opportunity for collaboration and growth,” Ashley McPhail, chief external affairs & administration officer at Texas Medical Center said in a press release. “The Netherlands has solidified its position as a global leader in the field of life sciences and health, with a thriving ecosystem of research institutions, innovative companies, and highly skilled professionals. This strategic partnership will bring positive benefits to patients, clinicians and industry partners on a global scale.”

This lifeline for international healthcare companies makes expansion into the United States far smoother. The Global Innovators Launch Pad allows for startup founders to take part in a 10-week residency at the TMC Innovation Factory that will teach them about foundational infrastructure, clinical evidence and funding in the US.

“Since Texas is an important hub for innovation in the MedTech and digital health sectors, the collaboration with Texas Medical Center creates opportunities for Dutch companies looking to expand their international reach. Vice versa, it gives companies in Texas access to the vibrant Dutch Life Sciences & Health sector,” said van Vilsteren.

That exchange includes members of the TMC gaining the opportunity to participate in the Health~Holland Visitors Programme (HVP), “Shaping the Healthcare of the Future.”

The annual event invites high-level representatives from the private sector, NGOs, knowledge institutions, healthcare providers and different tiers of government to share their expertise.

It's the fifth partnership of its kind for TMC, with the last one being with Ireland, announced last year. TMC's other global initiatives include accelerators with Denmark and the United Kingdom, both announced earlier this year.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.

View All Listings